BRINGING NEW PERSPECTIVES
TO SOFT TISSUE REPAIR
Events
American College of Surgeons Clinical Congress 2017
Colorado Therapeutics will present and exhibit at the American College of Surgeons (ACS) 103rd annual Clinical Congress held from October 22-26, 2017 at the San Diego Convention Center, in San Diego, California. Learn more at https://www.facs.org/clincon2017.
News
Colorado Therapeutics and Micro Interventional Devices Enter into a License Agreement for Use of the PolyCor™ Anchoring Technology
BROOMFIELD, Colo. – October 28, 2016 – Colorado Therapeutics LLC, a privately held medical device company with a proprietary technology platform for the production of innovative cross-linked tissue products, announced today that it has entered into a worldwide exclusive license agreement with Micro Interventional Devices, Inc. (MID), a leader in minimally invasive and catheter-based compliant… Read more »
Colorado Therapeutics Receives 510(k) Clearance for a Novel Xenograft Implant for Soft Tissue Repairs
– Series A Financing will be Opened to Support Commercial Launch – BROOMFIELD, CO – October 21, 2016 – Colorado Therapeutics LLC, a privately held medical device company with a proprietary technology platform for the production of innovative cross-linked tissue products, announced today that it has received 510(k) clearance from the U.S. Food and Drug… Read more »
Colorado Therapeutics Submits 510(k) for a Novel Xenograft Implant for Soft Tissue Repairs
– Colorado Therapeutics Closes Angel Financing Round and Will Open Series A Financing in Support of Anticipated Commercial Launch – BROOMFIELD, CO – January 28, 2016 – Colorado Therapeutics LLC, a privately held medical device company that is leveraging over 15 years of innovative and proprietary cross-linked tissue processing technology, announced today that it has… Read more »
Colorado Therapeutics Created and Launches New Website
BROOMFIELD, CO – April 20, 2015 – Colorado Therapeutics, LLC, a privately held emerging medical device company, has been created to leverage over 15 years of innovative and proprietary tissue processing technology. The Company has developed innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue matrix products for a broad range of soft… Read more »